Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Nov 5;24(11):1708–1715. doi: 10.1038/s41591-018-0224-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a, Kaplan–Meier estimates for fully adherent study participants (n = 996) after treatment with 7/7 or 6/7 dosing strategies. b, Multivariate analysis with total number of doses taken for study participants who took at least 4 months of treatment under 7/7 dosing strategies for 26 weeks (REMoxTB and RIFAQUIN trials), after adjustment for country and treatment duration. c, Multivariate analysis with total number of doses taken for study participants who took at least 4 months of treatment under 6/7 dosing strategies for 24 weeks (OFLOTUB trial), after adjustment for country and treatment duration. Effect sizes for country are available in Supplementary Table 7. In b and c, the HRs with 95% Wald CI are reported. ^aHazard ratio with 95% Wald CI for 6/7 dosing strategy relative to 7/7 dosing strategy for fully adherent population after adjustment for country and treatment duration. ^bTreatment duration <182 days, 21/110 (19%) unfavorable outcomes and treatment duration ≥182 days, 40/577 (7%) unfavorable outcomes. ^cTreatment duration <169 days, 21/155 (14%) unfavorable outcomes and treatment duration ≥169 days, 42/443 (9%) unfavorable outcomes.